Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus

Phytotherapy Research

Volumn 28, Issue 12, 2014, Pages 1796-1800

  Neerati, Prasad ^a   Devde, Raju ^b   Gangi, Anil Kumar ^a  

^a KAKATIYA UNIVERSITY   (India)

^b Kakatiya Medical College   (India)

Author keywords

Curcumin; Glyburide; Lipid profile; RP HPLC; Type 2 diabetic patients

Indexed keywords

CURCUMIN; GLIBENCLAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AREA UNDER FIRST MOVEMENT CURRE; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84918531375     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5201     Document Type: Article

References (23)

1. Anger GJ, Magomedova L, Piquette-Miller M. 2009. Impact of acute streptozotocin-induced diabetes on ABC transporter expression in rats. Chem. Biodivers 6: 1943-1959.
2. Appiah-Opang R, Commandeur J, Vugt-Lussenberg B, Vermeulen N. 2007. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 235: 83-91.
3. Brockmeier D, Grigoleit HG, Leonhardt H. 1985. Absorption of glybenclamide from different sites of gastro-intestinal tract. Eur J Clin Pharmacol 29: 193-197.
4. Darwiche G, Almer LO, Bjorgell O, Cederholm C, Nilsson P. 2001. Delayed gastric emptying rate in type 1 diabetics with cardiac autonomic neuropathy. J Diabetes Complication 15: 128-134.
5. Feldman JM. 1985. Glyburide: a second-generation sulfonylurea hypoglycaemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 5: 43-62.
6. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R. 1999. P-glycoprotein inhibition by glybenclamide and related compounds. Pflugers Arch 437: 652-660.
7. Ishiguchi T, Tada H, Nakagawa K, Yamamura T, Takahashi, T. 2002. Hyperglycemia impairs antro-pyloric coordination and delays gastric emptying in conscious rats. Aouton Neurosci 95: 112-120.
8. Jacobsen W, Kirchner G, Hallenslebem K. 1999. Comparison of cytochrome P-450 dependent metabolism and drug interactions of the 3-hydroxy-3 methyl glutaryl CoA reductase inhibitors. Drug Metab Dispos 27: 173-179.
9. Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM. 2008. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 57: 1576-1583.
10. Jonsson A, Hallengren B, Rydberg T, Melander A. 2001. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 3: 403-409.
11. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M. 2005. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 28: 937-939.
12. Mouly S, Paine MF. 2003. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20: 1595-1599.
13. Muthena P, Suryanarayana P, Shravan KG, Markpetrash J, Bhanu prakash RG. 2009. Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett 583: 3637-3642.
14. Na LX, Zhang YL, Li Y, Liu LY, Kong T, Sun CH. 2009. Curcumin improves insulin resistance in skeletal muscle of rats. Nut Metab Cardiovasc Dis 21: 526-533.
15. Nawa A, Fujita Hamabe W, Tokuyama S. 2010. Inducible nitric oxide synthase-mediated decrease of intestinal Pglycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci 86: 402-409.
16. Nohara S, Iwase M, Imoto H, Sasaki N, Nakamura U, Uchizono Y. 2006. Gastric emptying in patients with type 2 diabetes mellitus and diabetes associated with mitochondrial DNA 3243 mutation using 13C-octanoic acid breath test. J Diabetes Complications 20: 295-301.
17. Romiti N, Tongiani R, Cervelli F, Chieli E. 1998. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 62(25): 2349-2358.
18. Seo KI, Choi MS, Jung UJ, Kim HJ, Yeo J, Jeon SM. 2008. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 52: 995-1004.
19. Sharma S, Kulkarni SK, Chopra K. 2006a. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 33: 940-945.
20. Sharma S, Srinivas K, Kulkarni SK, Javed N, Agrawala, CK. 2006b. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 536: 256-266.
21. Shishodia S, Sethi G, Aggarwal B. 2005. Curcumin: getting back to the roots. Ann NY Acad Sci 1056: 206-217.
22. Soni KB, Kuttan R. 1992. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36: 273-275.
23. Yu Y, Hu SK, Yan H. 2008. The study of insulin resistance and leptin resistance on the model of simplicity obesity rats by curcumin. Zhonghua Yu Fang Yi Xue Za Zhi 42: 818-822.